{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Body Mass Index, Obesity, and Mortality - Part I: Associations and Limitations
Activity Steps
Purpose of Activity
Seventy-five percent of participants will be able to demonstrate knowledge about National Health and Nutrition Examination Survey (NHANES) datasets and the association and limitations of determining risk of mortality with use of body mass index (BMI) and other measures associated with obesity by achieving a posttest score of 70% or greater.Learning Objectives
After completing this continuing education activity you will be able to:
- Identify the association between body mass index (BMI), obesity, and mortality risk using data from the National Health and Nutrition Examination Survey (NHANES) datasets.
- Describe how mortality risk is impacted by bodyweight, body composition, and adiposity indicators.
- Explain findings of study analyses of truncal, intraabdominal, and visceral adipose tissue mass in relation to mortality risk.
Learning Outcomes
Seventy-five percent of participants will be able to demonstrate knowledge about National Health and Nutrition Examination Survey (NHANES) datasets and the association and limitations of determining risk of mortality with use of body mass index (BMI) and other measures associated with obesity by achieving a posttest score of 70% or greater.Disclosures
No funding was provided for the development of this manuscript. T.M. has grant/research support from NIDILRR, NIH, CDC, and PCORI and industry funding from Brigham and Women's Hospital with the overall sponsor as Metro International. He has received consulting fees from Novo Nordisk and editorial fees from the Obesity journal and PLoS One. In the last 24 months, D.B.A. has received personal payments or promises for same from Alkermes, Inc; Amin Talati Wasserman for KSF Acquisition Corp (Glanbia); Clark Hill, PLC; Kaleido Biosciences; Law Offices of Ronald Marron; Medpace/Gelesis; Novo Nordisk Fonden; Sports Research Corp; and Zero Longevity Science. D.B.A.'s institution, Indiana University, and the Indiana University Foundation have received funds or donations to support his research or educational activities from Eli Lilly and Company; Pfizer, Inc; Soleno Therapeutics; WW (formerly Weight Watchers); and numerous other for-profit and nonprofit organizations to support the work of the School of Public Health and the university more broadly. K.C.M. has received research funding and/or consulting fees in the last 24 months from the following: 89bio, Inc, Acasti Pharma Inc,Beren Therapeutics, Bragg Live Products, Cargill, Eli Lilly and Company, General Mills, Greenyn Biotechnology, Hass Avocado Board, Indiana University Foundation, Matinas BioPharma, MediFast, National Cattlemen's Beef Association, National Dairy Council, Naturmega, New Amsterdam Pharma, PepsiCo, and Pharmavite. Funding from these organizations was not used to support this article. The other authors have no conflicts of interest to disclose. This program has been reviewed and all potential or actual relevant financial relationships have been mitigated with author disclosures provided at the beginning of this article. No funding was provided for the development of this article. All other authors and planners have disclosed no potential relevant financial relationships or otherwise.
Credits:
- ANCC 2.0 CH
- DC - BON 2.0 CH
- FL - BON 2.0 CH
- GA - BON 2.0 CH
- NM - BON 2.0 CH
- SC - BON 2.0 CH
- WV - BOERN 2.0 CH